-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $4

Benzinga·06/18/2026 17:42:49
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and lowers the price target from $6 to $4.